Compare HUBC & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | PYPD |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 107.0M |
| IPO Year | 2022 | 2014 |
| Metric | HUBC | PYPD |
|---|---|---|
| Price | $0.15 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | ★ 1.1M | 96.0K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $3.40 |
| 52 Week High | $8.68 | $5.73 |
| Indicator | HUBC | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 54.36 |
| Support Level | $0.11 | $4.54 |
| Resistance Level | $0.31 | $5.58 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 0.17 | 92.06 |
Hub Cyber Security Ltd is engaged in developing reliable quality assurance systems that support process and product enhancement and also operates in the industry of secured data fabric. The company serves various organizations and institutions operating in the security, electronics, aviation, telecommunications, and banking. The company has two operating segments: Product and Technology Segment and Professional Services Segment. The majority of revenue comes from the professional services segment, which provides data and cybersecurity and system security and reliability solutions and related services such as consulting, planning, integrating and ongoing servicing of cybersecurity, risk management, reliability and security projects and fully managed corporate cybersecurity services.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.